A Phase 1, 2-part Study Of Pf-05221304 In Healthy Japanese Adults: Part 1 - Randomized, Double-blind, Crossover, Single Dose Assessment Of Pharmacokinetics And Safety; Part 2- Randomized, Double-blind, Placebo-controlled, Multiple Dose Assessment Of Safety, Tolerability And Pharmacokinetics Of Pf-05221304
Phase of Trial: Phase I
Latest Information Update: 03 Dec 2018
Price : $35 *
At a glance
- Drugs PF 5221304 (Primary)
- Indications Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Pfizer
- 26 Nov 2018 Status changed from recruiting to completed.
- 05 Sep 2018 Status changed from not yet recruiting to recruiting.
- 30 Jul 2018 New trial record